Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 4.55
CVM's Cash to Debt is ranked lower than
63% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CVM: 4.55 )
Ranked among companies with meaningful Cash to Debt only.
CVM' s Cash to Debt Range Over the Past 10 Years
Min: 0.85  Med: 251.74 Max: No Debt
Current: 4.55
Equity to Asset -0.34
CVM's Equity to Asset is ranked lower than
95% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CVM: -0.34 )
Ranked among companies with meaningful Equity to Asset only.
CVM' s Equity to Asset Range Over the Past 10 Years
Min: -0.34  Med: 0.69 Max: 0.98
Current: -0.34
-0.34
0.98
F-Score: 4
Z-Score: -30.24
M-Score: -5.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5212.16
CVM's Operating margin (%) is ranked lower than
90% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CVM: -5212.16 )
Ranked among companies with meaningful Operating margin (%) only.
CVM' s Operating margin (%) Range Over the Past 10 Years
Min: -190240  Med: -11287.71 Max: -1881.38
Current: -5212.16
-190240
-1881.38
Net-margin (%) -5269.60
CVM's Net-margin (%) is ranked lower than
90% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CVM: -5269.60 )
Ranked among companies with meaningful Net-margin (%) only.
CVM' s Net-margin (%) Range Over the Past 10 Years
Min: -154060  Med: -6210.31 Max: 6851.63
Current: -5269.6
-154060
6851.63
ROE (%) -813.10
CVM's ROE (%) is ranked lower than
98% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CVM: -813.10 )
Ranked among companies with meaningful ROE (%) only.
CVM' s ROE (%) Range Over the Past 10 Years
Min: -1352.47  Med: -182.07 Max: 48.78
Current: -813.1
-1352.47
48.78
ROA (%) -196.00
CVM's ROA (%) is ranked lower than
93% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CVM: -196.00 )
Ranked among companies with meaningful ROA (%) only.
CVM' s ROA (%) Range Over the Past 10 Years
Min: -199.98  Med: -90.18 Max: 25.01
Current: -196
-199.98
25.01
ROC (Joel Greenblatt) (%) -5945.96
CVM's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CVM: -5945.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CVM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5737.42  Med: -1101.41 Max: 687.95
Current: -5945.96
-5737.42
687.95
EBITDA Growth (3Y)(%) -10.20
CVM's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CVM: -10.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CVM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.7  Med: -12.60 Max: 17.2
Current: -10.2
-51.7
17.2
EPS Growth (3Y)(%) -15.70
CVM's EPS Growth (3Y)(%) is ranked lower than
64% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CVM: -15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CVM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.3  Med: -17.60 Max: 45
Current: -15.7
-55.3
45
» CVM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 62.71
CVM's P/S is ranked lower than
87% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. CVM: 62.71 )
Ranked among companies with meaningful P/S only.
CVM' s P/S Range Over the Past 10 Years
Min: 0  Med: 290.00 Max: 1660
Current: 62.71
0
1660
Current Ratio 1.29
CVM's Current Ratio is ranked lower than
85% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CVM: 1.29 )
Ranked among companies with meaningful Current Ratio only.
CVM' s Current Ratio Range Over the Past 10 Years
Min: 0.35  Med: 7.86 Max: 35
Current: 1.29
0.35
35
Quick Ratio 1.08
CVM's Quick Ratio is ranked lower than
83% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CVM: 1.08 )
Ranked among companies with meaningful Quick Ratio only.
CVM' s Quick Ratio Range Over the Past 10 Years
Min: 0.25  Med: 7.63 Max: 35
Current: 1.08
0.25
35
Days Sales Outstanding 48.26
CVM's Days Sales Outstanding is ranked higher than
66% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CVM: 48.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.33  Med: 168.81 Max: 230.53
Current: 48.26
48.33
230.53

Valuation & Return

vs
industry
vs
history
Price/Graham Number 0.74
CVM's Price/Graham Number is ranked higher than
81% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. CVM: 0.74 )
Ranked among companies with meaningful Price/Graham Number only.
CVM' s Price/Graham Number Range Over the Past 10 Years
Min: 0.87  Med: 1.76 Max: 3.16
Current: 0.74
0.87
3.16
Earnings Yield (Greenblatt) (%) -57.90
CVM's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CVM: -57.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CVM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -91.27  Med: 0.00 Max: 0
Current: -57.9
-91.27
0

More Statistics

Revenue(Mil) $1
EPS $ -0.44
Beta-1.90
Short Percentage of Float2.12%
52-Week Range $0.36 - 1.23
Shares Outstanding(Mil)129.97

Analyst Estimate

Sep16 Sep17 Sep18
Revenue(Mil) 1 2 2
EPS($) -0.41 -0.34 0.34
EPS without NRI($) -0.41 -0.34 0.34

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LSRN.Germany,
CEL-SCI Corp was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products. The Company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. Its investigational therapy, Multikine, is currently being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from Phase 1 and Phase 2 clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to review by the U.S. Food and Drug Administration, or FDA, in connection with CEL-SCI's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use. Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines and is manufactured in a proprietary manner in its manufacturing facility. The Company's patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses heteroconjugates to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own. Administered like a vaccine, LEAPS combines T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.
» More Articles for CVM

Headlines

Articles On GuruFocus.com
CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 
CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 
CELSCISci Corp Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
4:51 pm CEL-SCI Corp reports Q1 EPS of $0.02 vs. ($0.11) in prior year period; Feb 09 2016
CEL SCI CORP Files SEC form 10-Q, Quarterly Report Feb 09 2016
CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results Feb 09 2016
CEL-SCI To Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference Feb 08 2016
February Flaherty Financial Newsletter Features CEL-SCI Corporation's (NYSE MKT: CVM) Thrilling... Feb 04 2016
CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference Feb 03 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer... Feb 01 2016
CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial Feb 01 2016
NEW STORY CEL-SCI'S Chief Scientific Officer Discusses Cancer Immunotherapy Multikine Jan 25 2016
CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine Jan 25 2016
Cancer Immunotherapy - The Future of Cancer Treatment - What's Next in 2016 - Expert Dr. Eyal Talor,... Jan 21 2016
CEL SCI CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement Jan 15 2016
NEW STORY CEL-SCI Corporation to Present at the Noble Financial Capital Markets' 12th Annual... Jan 14 2016
CEL-SCI Corporation to Present at the Noble Financial Capital Markets’ 12th Annual Investor... Jan 14 2016
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 14 2016
NEW STORY CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum... Jan 08 2016
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum for 2016 Jan 08 2016
CEL-SCI Corp (CVM) Shows Strength: Stock Moves Up 8.3% Jan 07 2016
NEW STORY CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3... Jan 05 2016
CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and... Jan 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK